1.72 USD
▼-0.39-18.48%
盘后 1.90 0.00%
2026-09-16
市值
$7.53M
市盈率
—
EPS
-10.24
股息率
—
52 周区间
1.64 – 39.92
成交量
83.87K
Beta
2.90
目标价
68.00
52W 低 1.6452W 高 39.92
价格走势
公司简介
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses met...